drugset / Trial / NCT03009240
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of pevonedistat when given together with decitabine in treating patients with high risk acute myeloid leukemia. Pevonedistat and decitabine may stop the growth of cancer cells by blocking some of the enzymes need for cell growth.
Timeline
- Start
- 2017-08-21
- Primary completion
- 2026-03-19
- Completion
- 2026-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | — | Intravenous |
| Subject | Pevonedistat | Small molecule | — | Intravenous |